A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)

Protocol No
NEURO-ALEXION-ALX-NMO-501
Phase
N/A
Summary

This project is being done to collect the safety and effectiveness data for SOLIRIS or ULTOMIRIS as well as to compile data to characterize the progression and management of patients with AQP4+ NMOSD.

Description
Registry of Patients with AQP4+ NMOSD Treated with Alexion C5 Inhibitor Therapies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Brain, Spinal Cord, and Nervous System, Other (e.g. headache, autonomics)